Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Shares Outstanding (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Shares Outstanding for 8 consecutive years, with $103.4 million as the latest value for Q1 2026.

  • Quarterly Shares Outstanding rose 35.63% to $103.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $103.4 million through Feb 2026, up 35.63% year-over-year, with the annual reading at $101.8 million for FY2025, 34.19% up from the prior year.
  • Shares Outstanding for Q1 2026 was $103.4 million at Nurix Therapeutics, up from $101.8 million in the prior quarter.
  • The five-year high for Shares Outstanding was $103.4 million in Q1 2026, with the low at $44.9 million in Q1 2022.
  • Average Shares Outstanding over 5 years is $62.8 million, with a median of $49.1 million recorded in 2024.
  • The sharpest move saw Shares Outstanding grew 1.43% in 2022, then skyrocketed 55.73% in 2024.
  • Over 5 years, Shares Outstanding stood at $47.2 million in 2022, then grew by 3.28% to $48.7 million in 2023, then soared by 55.73% to $75.9 million in 2024, then soared by 34.19% to $101.8 million in 2025, then grew by 1.56% to $103.4 million in 2026.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $103.4 million, $101.8 million, and $76.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.